Robin Mathews1, Tracy Y Wang2, Emily Honeycutt2, Timothy D Henry3, Marjorie Zettler4, Michael Chang5, Gregg C Fonarow6, Eric D Peterson2. 1. Duke Clinical Research Institute, Durham, NC. Electronic address: robin.mathews@duke.edu. 2. Duke Clinical Research Institute, Durham, NC. 3. Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN. 4. Lilly, USA, LLC, Indianapolis, IN. 5. Mercy Heart Vascular Institute, Sacramento, CA. 6. Ahmanson-UCLA Cardiomyopathy Center, University of California at Los Angeles, Los Angeles, CA.
Abstract
BACKGROUND: Persistent use of secondary prevention therapies after acute myocardial infarction (MI) is critical to optimizing long-term outcomes. METHODS: Medication persistence was assessed among 7,955 MI patients in 216 hospitals participating in the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome study from 2010 to 2012. Persistence was defined as continuation of aspirin, adenosine diphosphate receptor inhibitors, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins from discharge to 6 months post-MI. Multivariable logistic regression modeling was used to determine factors associated with nonpersistence, defined as <80% persistence with all medication classes. RESULTS: Overall, 31% of MI patients stopped taking a least 1 medication by 6 months. The most common reasons cited for medications discontinuation were side effects and physician instruction (57%), whereas financial concerns were cited in 8% overall. After multivariable modeling, black race (odds ratio 1.36, 95% CI 1.15-1.62), older age (odds ratio 1.07, 95% CI 1.02-1.12), atrial fibrillation (odds ratio 1.67, 95% CI 1.33-2.09), dialysis (odds ratio 1.79, 95% CI 1.15-2.78), and depression (odds ratio 1.22, 95% CI 1.02-1.45) were associated with lower likelihood of persistence. Private insurance (odds ratio 0.85, 95% 0.76-0.95), prescription cost assistance (odds ratio 0.63, 95% CI 0.54-0.75), and outpatient follow-up arranged before discharge (odds ratio 0.89, 95% CI 0.80-0.99) were associated with higher persistence. CONCLUSIONS: Nearly one-third of MI patients are no longer persistent with their prescribed medications by 6 months. Patients at high risk for nonpersistence may be identified by clinical and sociodemographic features. These observations underscore key opportunities to optimize longitudinal use of secondary prevention therapies.
BACKGROUND: Persistent use of secondary prevention therapies after acute myocardial infarction (MI) is critical to optimizing long-term outcomes. METHODS: Medication persistence was assessed among 7,955 MI patients in 216 hospitals participating in the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome study from 2010 to 2012. Persistence was defined as continuation of aspirin, adenosine diphosphate receptor inhibitors, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins from discharge to 6 months post-MI. Multivariable logistic regression modeling was used to determine factors associated with nonpersistence, defined as <80% persistence with all medication classes. RESULTS: Overall, 31% of MI patients stopped taking a least 1 medication by 6 months. The most common reasons cited for medications discontinuation were side effects and physician instruction (57%), whereas financial concerns were cited in 8% overall. After multivariable modeling, black race (odds ratio 1.36, 95% CI 1.15-1.62), older age (odds ratio 1.07, 95% CI 1.02-1.12), atrial fibrillation (odds ratio 1.67, 95% CI 1.33-2.09), dialysis (odds ratio 1.79, 95% CI 1.15-2.78), and depression (odds ratio 1.22, 95% CI 1.02-1.45) were associated with lower likelihood of persistence. Private insurance (odds ratio 0.85, 95% 0.76-0.95), prescription cost assistance (odds ratio 0.63, 95% CI 0.54-0.75), and outpatient follow-up arranged before discharge (odds ratio 0.89, 95% CI 0.80-0.99) were associated with higher persistence. CONCLUSIONS: Nearly one-third of MI patients are no longer persistent with their prescribed medications by 6 months. Patients at high risk for nonpersistence may be identified by clinical and sociodemographic features. These observations underscore key opportunities to optimize longitudinal use of secondary prevention therapies.
Authors: Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro Journal: N Engl J Med Date: 2014-11-16 Impact factor: 91.245
Authors: L Halasyamani; S Kripalani; E Coleman; J Schnipper; C van Walraven; J Nagamine; P Torcson; T Bookwalter; T Budnitz; D Manning Journal: J Hosp Med Date: 2006-11 Impact factor: 2.960
Authors: Judith M Kramer; Bradley Hammill; Kevin J Anstrom; Donald Fetterolf; Richard Snyder; John P Charde; Barbara S Hoffman; Nancy Allen LaPointe; Eric Peterson Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: P Michael Ho; John A Spertus; Frederick A Masoudi; Kimberly J Reid; Eric D Peterson; David J Magid; Harlan M Krumholz; John S Rumsfeld Journal: Arch Intern Med Date: 2006-09-25
Authors: Christopher L Roy; Eric G Poon; Andrew S Karson; Zahra Ladak-Merchant; Robin E Johnson; Saverio M Maviglia; Tejal K Gandhi Journal: Ann Intern Med Date: 2005-07-19 Impact factor: 25.391
Authors: Christopher M Celano; Ariana M Albanese; Rachel A Millstein; Carol A Mastromauro; Wei-Jean Chung; Kirsti A Campbell; Sean R Legler; Elyse R Park; Brian C Healy; Linda M Collins; James L Januzzi; Jeff C Huffman Journal: Psychosom Med Date: 2018 Jul/Aug Impact factor: 4.312
Authors: Alexander C Fanaroff; Shuang Li; Laura E Webb; Vincent Miller; Ann Marie Navar; Eric D Peterson; Tracy Y Wang Journal: Circ Cardiovasc Qual Outcomes Date: 2018-04
Authors: Michael J Stirratt; Jeffrey R Curtis; Maria I Danila; Richard Hansen; Michael J Miller; C Ann Gakumo Journal: J Gen Intern Med Date: 2018-02 Impact factor: 5.128
Authors: Ann Marie Navar; Matthew T Roe; Jennifer A White; Christopher P Cannon; Yuliya Lokhnygina; L Kristin Newby; Robert P Giugliano; Andrew M Tershakovec; Eugene Braunwald; Robert M Califf; Michael A Blazing Journal: Circ Cardiovasc Qual Outcomes Date: 2019-01
Authors: Maarit J Korhonen; Jennifer G Robinson; Izabela E Annis; Ryan P Hickson; J Simon Bell; Juha Hartikainen; Gang Fang Journal: J Am Coll Cardiol Date: 2017-09-26 Impact factor: 24.094
Authors: Reynaria Pitts; Stacie L Daugherty; Fengming Tang; Philip Jones; P Michael Ho; Thomas T Tsai; John Spertus; Thomas M Maddox Journal: Clin Cardiol Date: 2017-04-07 Impact factor: 2.882